Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab

Antibody-based immunotherapy is increasingly employed to treat acute lymphoblastic leukemia (ALL) patients. Many T-ALL cells express CD38 on their surface, which can be targeted by the CD38 antibody daratumumab (DARA), approved for the treatment of multiple myeloma. Tumor cell killing by myeloid cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Baumann, Niklas, Arndt, Christian, Petersen, Judith, Lustig, Marta, Rösner, Thies, Klausz, Katja, Kellner, Christian, Bultmann, Miriam, Bastian, Lorenz, Vogiatzi, Fotini, Leusen, Jeanette H. W., Burger, Renate, Schewe, Denis M., Peipp, Matthias, Valerius, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427194/
https://www.ncbi.nlm.nih.gov/pubmed/36052078
http://dx.doi.org/10.3389/fimmu.2022.949140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427194/
https://www.ncbi.nlm.nih.gov/pubmed/36052078
http://dx.doi.org/10.3389/fimmu.2022.949140

Ejemplares similares